Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Chemotherapy

Trial Profile

A Phase 3 Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Chemotherapy

Planning
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Uproleselan-sodium (Primary) ; Decitabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Feb 2018 According to a GlycoMimetics media release, Professor Gerwin Huls is the principal investigator at HOVON and Professor of Haematology at University Medical Centre Groningen.
    • 08 Feb 2018 According to a GlycoMimetics media release, this trial is expected to start this year and will be conducted in five countries across Europe.
    • 08 Feb 2018 According to a GlycoMimetics media release, the company has entered into an agreement with the Haemato Oncology Foundation for Adults in the Netherlands (HOVON) group to initiate clinical trial startup activities for this planned trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top